An Initial Open Trial of a Brief Behavioral Activation Treatment for Depression and Medication Adherence in HIV-Infected Patients.
Matthew T Tull, Christopher R Berghoff, Joseph R Bardeen...
https://pubmed.ncbi.nlm.nih.gov/28799413/Actively Recruiting
Led by University of Maryland, College Park · Updated on 2026-04-27
160
Participants Needed
4
Research Sites
8 weeks
Total Duration
This research aims to evaluate a peer-led, brief behavioral intervention designed to improve medication adherence for opioid use disorder MOUD and reduce polysubstance use among patients with opioid use disorder OUD and polysubstance use in underserved areas. The study focuses on a behavioral activation BA approach delivered by trained peer recovery specialists PRSs and compares it to treatment as usual TAU over a 12-month period. The trial addresses challenges in OUD treatment retention, especially in communities with limited access to addiction care and rising stimulant use. Participants will be randomly assigned to either the Peer Activate intervention or enhanced treatment as usual. Those in the Peer Activate group will receive about six weekly core sessions, lasting 30 minutes to one hour, led by PRSs teaching behavioral activation and problem-solving skills. Additionally, up to six optional booster sessions are available to reinforce these skills. The TAU group receives standard telemedicine services enhanced with community referrals and follow-ups, plus regular meetings with addiction medicine physicians and PRSs for general support. Throughout the study, participants will be monitored with urinalysis and self-reports to assess polysubstance use, treatment retention, and medication adherence over six months. Researchers will also track intervention attendance, uptake, and fidelity. The trial includes multiple assessments to measure problems related to substance use and the effectiveness of peer-delivered behavioral activation in improving outcomes for patients receiving telemedicine buprenorphine treatment. Total participation and follow-up last at least 12 months.
CONDITIONS
Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention
M
Morgan S Anvari, BA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Maryland, College Park
Lead Sponsor
University of Maryland, Baltimore
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Peer‑Activate intervention | Treatment as Usual | External telemedicine MOUD retention support |
|---|---|---|---|
| What it is | A behavioral activation intervention delivered by peer recovery specialists alongside MOUD via telemedicine to improve retention and reduce polysubstance use | Standard telemedicine‑based MOUD care without added peer‑delivered behavioral activation | Telemedicine‑based medication for opioid use disorder (MOUD) retention support |
| Role in trial | Assigned investigational intervention | Assigned comparator arm as usual care | Represents current‑care context outside the trial, not randomized |
| Primary use | Improve retention on MOUD and reduce polysubstance use | Maintain standard retention and substance use monitoring via telemedicine MOUD | Support retention in MOUD through telemedicine care delivery |
| How it is given or performed | Delivered via approximately six weekly core sessions (30–60 minutes) by peer specialists, plus up to six optional booster sessions | Usual telemedicine MOUD care without added behavioral activation sessions | MOUD delivered via telemedicine visits without added behavioral activation, following standard practice |
| Evidence status | Effectiveness currently being evaluated in this randomized trial | Standard care with unknown comparative efficacy vs behavioral activation | Telemedicine‑based MOUD care is associated with higher retention compared to in‑person services |
| Important risks | Potential for psychological distress during behavioral activation sessions not yet characterized | Risks associated with standard MOUD telemedicine delivery as usual | Telemedicine MOUD retention strategies generally safe as per practice studies |
| Important limitations | Effectiveness and feasibility not yet established beyond trial; generalizability to diverse settings remains unproven | Retention outcomes may vary by program structure, patient access and engagement factors | Retention improvements observed may not apply to polysubstance‑using populations or underserved areas specifically |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Approximately 12 weeks
Participants receive peer-delivered behavioral activation sessions to support opioid use disorder treatment retention and reduce polysubstance use. This includes about six weekly core sessions and up to six optional booster sessions.
Weekly sessions for up to 12 weeks
Duration - Up to 6 months
Participants are followed for ongoing assessment of treatment retention, substance use, and adherence over six months after starting the intervention.
Regular assessments during the 6-month follow-up period
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Matthew T Tull, Christopher R Berghoff, Joseph R Bardeen...
https://pubmed.ncbi.nlm.nih.gov/28799413/Matthew J Mimiaga, Sari L Reisner, David W Pantalone...
https://pubmed.ncbi.nlm.nih.gov/23030605/David A Richards, David Ekers, Dean McMillan...
https://pubmed.ncbi.nlm.nih.gov/27461440/Stacey B Daughters, Jessica F Magidson, Deepika Anand...
https://pubmed.ncbi.nlm.nih.gov/28963853/Jessica F Magidson, John A Joska, Kristen S Regenauer...
https://pubmed.ncbi.nlm.nih.gov/31082664/Karin A Mack, Christopher M Jones, Michael F Ballesteros
https://pubmed.ncbi.nlm.nih.gov/29145698/J F Magidson, C W Lejuez, T Kamal...
https://pubmed.ncbi.nlm.nih.gov/27478619/R E Glasgow, T M Vogt, S M Boles
https://pubmed.ncbi.nlm.nih.gov/10474547/Enola Proctor, Hiie Silmere, Ramesh Raghavan...
https://pubmed.ncbi.nlm.nih.gov/20957426/Jessica F Magidson, Stephanie M Gorka, Laura MacPherson...
https://pubmed.ncbi.nlm.nih.gov/21310539/University of Maryland, College Park
Lead Sponsor
University of Maryland, Baltimore
Collaborating Sponsor